GigaGen Publishes Study in Peer-Reviewed Journal mAbs, Validating Feasibility and Benefit of Rapid Parallel Immunization Protocols for Discovery of Novel Monoclonal Antibodies

,

GigaGen Inc., a biopharmaceutical company developing novel antibody therapies, today announced the publication of a study that shows the feasibility and benefit of its Surge™ antibody discovery and engineering platform for rapid monoclonal antibody discovery using multiple immunization protocols in parallel. The study has been published online in the peer-reviewed scientific journal mAbs, and it will be available as the cover article in the upcoming July printed issue.

Read the full press release.

STAT: GigaGen CEO Dave Johnson, PhD, discusses why biotech execs need to create an environment that fosters a truly scientific culture

,

“What traditions do you want to follow for your baby?” asked the midwife leading our prenatal education group.

As we went around the circle of parents-to-be, most couples discussed holiday traditions, camping trips, and weekend routines. When it was my turn to share, I thought about the pseudoscience that had been espoused in this group — the alleged benefits of eating the placenta, theories about the harmful effects of vaccines, and the like.

“I want a facts-based, scientific household,” I said. “For example, is breastfeeding better than formula? To me the only thing that matters is the clear scientific consensus that breastfed infants grow up to be, on average, advantaged in some way — maybe healthier or smarter.”

Read the full story.

GigaGen CEO David Johnson to Present on Surge Technology at 2019 Antibody Engineering & Therapeutics Asia Meeting

,

GigaGen Inc., a biopharmaceutical company developing novel antibody therapies, today announced that David Johnson, Ph.D., chief executive officer, will present at the 2019 Antibody Engineering & Therapeutics Asia Meeting. Dr. Johnson will also co-chair the presentation, which will take place at 8:45 a.m. JST on February 26, 2019, at the Hilton Tokyo Bay Hotel in Tokyo, Japan.

Read the full press release.

GigaGen Publishes Study Demonstrating Optimal Method for Selecting OX40 Therapeutic Candidates from Antibody Repertoires

,

GigaGen Inc., a biopharmaceutical company developing novel antibody therapies, today announced the publication of a study showing how it adapted its Surge™ antibody discovery and engineering platform to improve selection of OX40 agonists. The study has been published online in the peer-reviewed scientific journal, Antibodies, as part of the special issue Antibody Repertoire Mining for Immune Profiling, Antibody Discovery and Vaccine Design.

Read the full press release.

GigaGen Promotes Adam Adler, Ph.D., to Chief Scientific Officer

,

GigaGen Inc., a biopharmaceutical company developing novel antibody therapies, today announced the promotion of Adam Adler, Ph.D., to Chief Scientific Officer (CSO). Previously, Dr. Adler was the company’s Vice President of Research and Development. In addition, Gigagen has promoted Rena Mizrahi, Ph.D to Vice President of Process Development and Catherine Medina to Vice President of Operations.

Read the full press release.

GigaGen Announces Appointment of Erica Stone, Ph.D., as Director, Immuno-Oncology

,

GigaGen Inc., a biopharmaceutical company developing novel antibody therapies, today announced that Erica Stone, Ph.D., has joined the company as director, immuno-oncology.

“We welcome award-winning immunologist Dr. Stone to the GigaGen team,” said Dave Johnson, Ph.D., CEO of GigaGen. “Dr. Stone brings with her a deep understanding of the tumor microenvironment and checkpoint inhibitors that is perfectly paired with our novel antibody discovery and engineering platform, Surge. Surge enables us to uncover new antibodies that have historically been missed by traditional discovery methods such as hybridoma, and with Dr. Stone’s expertise we look forward to identifying immuno-oncology drug candidates with the greatest potential to improve patient treatment.”

Read the full press release.

 

GigaGen CEO David Johnson to Present at 2018 Antibody Engineering & Therapeutics Meeting

,

GigaGen Inc., a biopharmaceutical company developing novel antibody therapies, today announced that David Johnson, Ph.D., chief executive officer, will present at the 2018 Antibody Engineering & Therapeutics Meeting. Dr. Johnson’s presentation will take place at 3:15 p.m. PST on December 9, 2018, at the Manchester Grand Hyatt in San Diego, Calif.

Read the full press release.

GigaGen CEO David Johnson to Present on Development of Recombinant Polyclonal Therapies for Infectious Disease at 10th Annual PEGS Summit Europe

,

GigaGen Inc., a biopharmaceutical company developing novel antibody therapies, today announced that David Johnson, Ph.D., Founder and Chief Executive Officer, will present on the development of highly diverse, functional antibodies for infectious disease utilizing Surge technology at the 10th Annual Protein & Antibody Engineering Summit (PEGS) in Europe. Dr. Johnson’s invited podium presentation is titled “Microfluidics and Genomics for Polyclonal and Monoclonal Antibody Drugs for Infectious Disease” and will take place during the Engineering Antibodies conference at 11:15 a.m. GMT on November 13, 2018, at the Libson Congress Center in Libson, Portugal.

Read the full press release.

 

GigaGen to Present Data on Immuno-Oncology Pipeline at the Society for Immunotherapy of Cancer (SITC) 2018 Annual Meeting

,

GigaGen Inc., a biopharmaceutical company developing novel antibody therapies, today announced a data presentation at the 33rd Annual Meeting of the Society for Immunotherapy of Cancer (SITC). Adam Adler, Ph.D., Vice President of Research and Development, will present on the antibody drug candidates discovered by the company’s industry-leading Surge technology against 17 unique immuno-oncology targets. The conference takes place November 7-11, 2018 at the Walter E. Washington Convention Center in Washington, D.C.

Read the full press release.

 

Genetic Engineering & Biotechnology News: Microfluidic dragnet catches most-wanted antibodies – GigaGen exhaustively interrogates antibodies to find drug candidates

,

“Scrappy.” That’s a one-word summation of GigaGen’s approach to both the business and science of biotech.

“When you’re a new company, you have to be scrappy and clever. When I founded GigaGen in 2011, I didn’t have a big war chest of money, so I had to find a way to be competitive. That’s central for survival,” says Dave Johnson, Ph.D., CEO of GigaGen.

Surge Workflow Performs Complete Interrogation

“Competitive” means “innovative” to Dr. Johnson. That drive to innovate resulted in a proprietary workflow called Surge, which he says not only interrogates every antibody in the immune system, but does it 10 times faster than other technologies.
Read the full story.